面向新的抗炎药物:设计,合成和评估向XIAP-BIR2的分子
Marc Farag1, Nicolas Guedeney1, Florian Schwalen1
1Department, Normandie Univ, UNICAEN, CERMN, bd Becquerel, F-14000, Caen, Cedex, France.
ChemMedChem
|October 4, 2024
概括
研究人员开发了针对XIAP-BIR2的新型小分子,以抑制炎症. 化合物20c选择性地阻断NOD1/2通路,为克罗恩病等炎症性疾病提供潜在的治疗方法.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 与X染色体相关的亡蛋白抑制剂 (XIAP) 调节细胞生存和炎症信号传递.
- XIAP-BIR2域相互作用与NOD2介导的炎症性疾病 (如克罗恩病) 有关.
- 准XIAP-RIPK2相互作用为炎症状况提供了治疗潜力.
研究的目的:
- 设计,合成和评估具有选择性结合XIAP-BIR2域的小分子.
- 为了确定能够破坏XIAP-RIPK2相互作用的强效抑制剂.
- 开发针对NOD1/2信号的新型抗炎化合物.
主要方法:
- 跨学科的药物设计方法.
- 一个初始片段库的合成,用于XIAP抑制查.
- 基于结构的药物设计和使用增长战略的化合物优化.
- 对XIAP-BIR2对XIAP-BIR3域的复合选择性的评估.
- 基于细胞的测试以确认NOD1/2信号通路的阻塞.
主要成果:
- 成功合成了针对XIAP的小分子.
- 对XIAP-BIR2对XIAP-BIR3.3具有高选择性的化合物20c的鉴定.
- 在细胞模型中证明化合物20c能够阻断NOD1/2信号传递的能力.
- 验证化合物20c作为炎症途径的强有力的抑制剂.
结论:
- 已经合成了选择性抑制XIAP-BIR2的新型小分子.
- 化合物20c有效地阻断了纤维素中的NOD1/2信号,显示出抗炎作用的潜力.
- 这些发现为开发用于NOD2介导炎症疾病的新疗法铺平了道路.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.1K
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.2K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
